Abionic

Epalinges, Switzerland Founded: 2010 • Age: 16 yrs
Point-of-care diagnostic tools for allergy profiles are provided.

About Abionic

Abionic is a Healthcare company based in Epalinges (Switzerland) founded in 2010 by Iwan MΓ€rki and Nicolas Durand. Point-of-care diagnostic tools for allergy profiles are provided. Abionic has raised $28.94 million across 4 funding rounds from investors including Zurcher Kantonalbank, Pierangelo Bottinelli and Philippe Glatz. Its chief executive, as recorded, is Patrick Pestalozzi. Abionic offers products and services including abioSCOPE and PSP Assay. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Bacterial.

Company details

Abionic was founded in 2010 and is based in Epalinges, Switzerland. Diagnostic tools for allergies are developed by the company within the healthcare sector. Operations focus on point-of-care solutions, including the abioSCOPE device for measuring IgE concentrations from blood samples, the abioGUIDE application for report viewing on mobile devices, and screening capsules that assess respiratory allergies using minimal blood volume.

  • Headquarters Epalinges, Switzerland
  • Founders Iwan Märki, Nicolas Durand
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website abionic.com
  • Social LinkedIn X Facebook
Operational Areas
Key Metrics
  • Total Equity Funding
    $28.94M (USD)

    in 4 rounds

  • Latest Funding Round
    $21.13M (USD), Series C

    Mar 2018

  • Investors

Products & Services of Abionic

Abionic offers a comprehensive portfolio of products and services, including abioSCOPE and PSP Assay.

abioSCOPE
Diagnostic Platform

Rapid tool for sepsis detection from blood samples in minutes.

PSP Assay
Biomarker Test

Test to detect sepsis risk using Pancreatic Stone Protein.

Funding Insights of Abionic

Abionic has successfully raised a total of $28.94M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $21.13 million completed in March 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $28.94M
  • Total Rounds 4
  • Last Round Series C β€” $21.13M
  • First Round $127,765

    (Oct 2010)

  • Investors Count 15

All 4 funding rounds of Abionic with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2018$21.13MSeries C–Pierangelo Bottinelli
Oct 2014$3.99MSeries B––
Apr 2012$3.7MSeries A–MedHoldings
Oct 2010$127,765Seed–Venture Kick
–
Valuation history

15 investors in total: 9 institutional and 6 angel.

Investors in Abionic

Abionic has secured backing from 15 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include Zurcher Kantonalbank, Pierangelo Bottinelli and Philippe Glatz.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
Venture capital firm focused on science and tech-driven startups
verve.vcBerlin, Germany
Investment in early-stage medical device and life science companies with network support.
blueocean-ventures.com
Business Angels Switzerland is focused on investing in innovative startups.
businessangels.chWorb, Switzerland
fongitseedinvest.com
medholdings.com
Early-stage tech startups in Switzerland and the US are funded.
polytechventures.chEcublens, Switzerland
University backed startup accelerator
venturekick.chSchlieren, Switzerland
Commercial banking services are provided across Switzerland by Zurcher Kantonalbank.
1870zkb.chZurich, Switzerland
Investment management services are provided by Drexel Morgan & Co.
1979drexelmorgan.comRadnor, United States

Pierangelo Bottinelli

unknown_8dc5c7b1b2944c47b
Premium access

Investor details for Abionic

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Abionic

11 people are tracked at Abionic (8 in leadership, 3 in board & advisors).

NameRoleGroup
Iwan Märki
Co-Founder & CTOLeadership
Nicolas Durand
Co-FounderLeadership
Patrick Pestalozzi
CEOLeadership
Stéphane Broillet
Head of EngineeringLeadership
François Ventura
Chief Medical OfficerLeadership
Jelena Nesic
Head of QCLeadership
Jean-Marc Reck
Head Of Human Resources And AdministrationLeadership
Guillaume Haquette
Chief Biology OfficerLeadership
Martine Reindle
President of the Board of DirectorsBoard & advisors
Nader Donzel
DirectorBoard & advisors
Eric Cornut
DirectorBoard & advisors
Premium access

Complete people profiles for Abionic

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Abionic

3 dated milestones of Abionic across 8 years, from founding to its latest funding, stage changes and deals.

  1. Founded Abionic is founded.
  2. Funding First funding round of $128K.
  3. Funding Latest funding round, Series C, of $21.1M.

Web traffic of Abionic

Websites that share an audience with Abionic (abionic.com).

Similar websites

Websites whose visitors overlap most with Abionic. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
biocartis.com
100%
10.5K#2,065,137View details
acimmune.com
99%
11.3K#1,671,085View details
hayesinc.com
63%
View details
acplus.com
63%
7.1K#3,043,935View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Abionic

Premium access

Complete news archive for Abionic

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Abionic

Abionic was founded in 2010.

Abionic is headquartered in Epalinges, Switzerland. It is registered at Epalinges, Vaud, Switzerland.

Patrick Pestalozzi is the CEO of Abionic, as recorded in our data.

Abionic is a funded company, having raised a total of $28.94M across 4 funding rounds to date. The company's 1st funding round was a Seed of $127.77K, raised on Oct 2010.

Abionic was founded in 2010 and is based in Epalinges, Switzerland. Diagnostic tools for allergies are developed by the company within the healthcare sector. Operations focus on point-of-care solutions, including the abioSCOPE device for measuring IgE concentrations from blood samples, the abioGUIDE application for report viewing on mobile devices, and screening capsules that assess respiratory allergies using minimal blood volume.

Abionic offers abioSCOPE and PSP Assay.

Abionic has 15 investors. Key investors include Zurcher Kantonalbank, Pierangelo Bottinelli, Philippe Glatz, Arkady Volozh, and Peter Brabeck-Letmathe.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available